These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34717237)

  • 21. Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity.
    Zwergel C; Di Bello E; Fioravanti R; Conte M; Nebbioso A; Mazzone R; Brosch G; Mercurio C; Varasi M; Altucci L; Valente S; Mai A
    ChemMedChem; 2021 Mar; 16(6):989-999. PubMed ID: 33220015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of thiophene-based hydroxamate derivatives as HDACis with antitumor activities.
    Yang F; Han L; Zhao N; Yang Y; Ge D; Zhang H; Chen Y
    Future Med Chem; 2020 Apr; 12(8):655-672. PubMed ID: 32202140
    [No Abstract]   [Full Text] [Related]  

  • 23. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
    Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W
    Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies.
    Namballa HK; Anchi P; Lakshmi Manasa K; Soni JP; Godugu C; Shankaraiah N; Kamal A
    Bioorg Chem; 2021 Dec; 117():105461. PubMed ID: 34753060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
    Cheng C; Yun F; Ullah S; Yuan Q
    Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells.
    Zhang K; Yao Y; Tu Z; Liao C; Wang Z; Qiu Y; Chen D; Hamilton DJ; Li Z; Jiang S
    Future Med Chem; 2020 Feb; 12(4):311-323. PubMed ID: 31782319
    [No Abstract]   [Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
    Krieger V; Hamacher A; Gertzen CGW; Senger J; Zwinderman MRH; Marek M; Romier C; Dekker FJ; Kurz T; Jung M; Gohlke H; Kassack MU; Hansen FK
    J Med Chem; 2017 Jul; 60(13):5493-5506. PubMed ID: 28574690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors.
    Abdelkarim H; Neelarapu R; Madriaga A; Vaidya AS; Kastrati I; Karumudi B; Wang YT; Taha TY; Thatcher GRJ; Frasor J; Petukhov PA
    ChemMedChem; 2017 Dec; 12(24):2030-2043. PubMed ID: 29080240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects.
    Trivedi P; Adhikari N; Amin SA; Jha T; Ghosh B
    Eur J Pharm Sci; 2018 Nov; 124():165-181. PubMed ID: 30171982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorescent Nanohybrids from ZnS/CdSe Quantum Dots Functionalized with Triantennary,
    Chen CT; Salunke S; Wei TT; Tang YA; Wang YC
    ACS Appl Bio Mater; 2021 Mar; 4(3):2475-2489. PubMed ID: 35014366
    [No Abstract]   [Full Text] [Related]  

  • 32. Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression.
    Lu Y; Feng Y; Li Z; Li J; Zhang H; Hu X; Jiang W; Shi T; Wang Z
    Eur J Med Chem; 2022 Jan; 227():113908. PubMed ID: 34656900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma.
    Zhai S; Zhang H; Chen R; Wu J; Ai D; Tao S; Cai Y; Zhang JQ; Wang L
    Eur J Med Chem; 2021 Dec; 225():113824. PubMed ID: 34509167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3).
    Chen H; Yang Z; Ding C; Xiong A; Wild C; Wang L; Ye N; Cai G; Flores RM; Ding Y; Shen Q; Zhou J
    Eur J Med Chem; 2014 Jul; 82():195-203. PubMed ID: 24904966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors.
    Chen Y; Zhang L; Zhang L; Jiang Q; Zhang L
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):425-436. PubMed ID: 33445997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities.
    Zhang L; Zhang Y; Chou CJ; Inks ES; Wang X; Li X; Hou J; Xu W
    ChemMedChem; 2014 Mar; 9(3):638-48. PubMed ID: 24227760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Synthesis and anti-tumor activities of N-(aminopyridine) benzamide derivaties].
    Feng J; Li JQ
    Yao Xue Xue Bao; 2009 Dec; 44(12):1376-82. PubMed ID: 21351472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, Synthesis and in Vitro Tumor Cytotoxicity Evaluation of 3,5-Diamino-N-substituted Benzamide Derivatives as Novel GSK-3β Small Molecule Inhibitors.
    Zhou Y; Zhang L; Fu X; Jiang Z; Tong R; Shi J; Li J; Zhong L
    Chem Biodivers; 2019 Sep; 16(9):e1900304. PubMed ID: 31338947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting breast cancer stem cells by novel HDAC3-selective inhibitors.
    Hsieh HY; Chuang HC; Shen FH; Detroja K; Hsin LW; Chen CS
    Eur J Med Chem; 2017 Nov; 140():42-51. PubMed ID: 28923385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.